Akèy › Kansè pwostat › Kalifòni › Orange
Etid klinik pou Kansè pwostat nan Orange, CA
14 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Orange (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Ap rekriteFaz 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Ap rekriteFaz 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Ap rekriteFaz 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 3
- University of California Irvine, Orange
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Ap rekriteFaz 3
- Univ Cali Irvine ALS Neuromuscular, Orange
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Ap rekriteFaz 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0006), Orange
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Ap rekriteFaz 3
- UC Irvine Health, Orange
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Ap rekriteFaz 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Ap rekriteFaz 1
- UCI Health Chao Family Comprehensive Cancer Center, Orange
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ap rekriteFaz 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Ap rekriteFaz 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Ap rekriteFaz 1/2
- UC Irvine Medical Center, Orange
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Ap rekriteFaz 4
- St. Joseph Hospital, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Orange
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN42 etid
- Seattle, WA42 etid
- Washington, DC38 etid
Lòt etid nan Orange
- Kansè Poumon ki pa ti selil25 etid
- Kansè Metastatik20 etid
- Kansè kolorektal16 etid
- Kansè ovè16 etid
- Kansè pankreyas15 etid
- Kansè nan tete14 etid
- Kansè poumon14 etid
- Kansè fwa (Kasinòm epatoselilè)14 etid
- Melanom14 etid
- Leksemi mieloïd egi13 etid
- Kansè (tout kalite)13 etid
- Kansè lestomak13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.